Pricing Log in Create free account
Friday 6 November 2026 Export LH’s income statement to Excel — free account

Labcorp Holdings Inc.

LH Healthcare Diagnostics & Research

Labcorp Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.0 billion, up 7.25% from fiscal 2024.

Revenue
+6.92%
EPS
+3.18%
Free cash flow
+44.7%
Total debt
+3.21%

Quarter to September 2026, against a year earlier

364.47 1.17 +0.32%
Market cap
$29.5B
P/E
29.5×
Fwd P/E
26.7×
Dividend yield
0.79%
F-score
8/9
Altman Z
3.02
Beneish M
−2.55
Dividend safety
74/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Labcorp Holdings Inc. 10-K filed Feb 24, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 1:51 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 25, 2025: 36 added · 164 removed · 52 modified; 4 moved without change

  1. Modified

    Labcorp® Holdings Inc. (Labcorp or the Company) is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the The Company provides insights and accelerates innovations to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. The During 2025, the Company’s nearly 70,00071,000 employees serveserved clients in approximately 100 countries and performed more than 750 million tests for patients around the world. In addition, the Company provided support for more than 7585% of the new drugs and therapeutic products approved in 20242025 by the FDA, and performed more than 700 million tests annually for patients around the world.